Skip to main content

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Associate Professor of Haematology
Oxford University and Lead of the Haematology and Lymphoma Service
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Please give us a review of the current response rates for treatment options deployed in PTCL-TFH; and, especially, how biomarker-driven taxonomization of PTCL into distinct subtypes is guiding approaches.

Please give us a review of the current response rates for treatment options deployed in PTCL-TFH; and, especially, how biomarker-driven taxonomization of PTCL into distinct subtypes is guiding approaches.

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Can you take us through your diagnostic protocols, biomarker panels, and pathway approaches to establish the presence of PTCL-TFH; and, your considerations in those patients who have relapsed/resistant PTCL-TFH?

Can you take us through your diagnostic protocols, biomarker panels, and pathway approaches to establish the presence of PTCL-TFH; and, your considerations in those patients who have relapsed/resistant PTCL-TFH?

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Can you discuss what we learned from the PRIMO trial that focused on the efficacy, actionable outcome signals observed with duvelisib in this trial, and the safety of the dual delta-gamma PI3K inhibitor, duvelisib?

Can you discuss what we learned from the PRIMO trial that focused on the efficacy, actionable outcome signals observed with duvelisib in this trial, and the safety of the dual delta-gamma PI3K inhibitor, duvelisib?

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Given duvelisib’s strong response and survival signals in PTCL-TFH from the PRIMO study, how did these findings influence the TERZO trial’s design, dosing strategy, and outcome goals?

Given duvelisib’s strong response and survival signals in PTCL-TFH from the PRIMO study, how did these findings influence the TERZO trial’s design, dosing strategy, and outcome goals?

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Duvelisib is being deployed for the treatment of R/R PTCL-TFH as well as for bridging patients who are awaiting allograft stem cell transplant. Can you discuss similarities and differences between U.S. and European approaches?

Duvelisib is being deployed for the treatment of R/R PTCL-TFH as well as for bridging patients who are awaiting allograft stem cell transplant. Can you discuss similarities and differences between U.S. and European approaches?

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Based on the PRIMO Phase 2 study evaluating duvelisib in PTCL-TFH, how should oncologists managing patients with this variant of PTCL-TFH think about deploying this dual gamma-delta PI3K inhibitor in the R/R subgroup afflicted with this PTCL subtype?

Based on the PRIMO Phase 2 study evaluating duvelisib in PTCL-TFH, how should oncologists managing patients with this variant of PTCL-TFH think about deploying this dual gamma-delta PI3K inhibitor in the R/R subgroup afflicted with this PTCL subtype?

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil